| scholarly article | Q13442814 |
| P50 | author | Dirk Schadendorf | Q32649390 |
| P2093 | author name string | Elisabeth Livingstone | |
| Lisa Zimmer | |||
| Uwe Hillen | |||
| Arne Becker | |||
| Stephanie Dömkes | |||
| P433 | issue | 3 | |
| P921 | main subject | panniculitis | Q780629 |
| P304 | page(s) | 357-361 | |
| P577 | publication date | 2012-01-16 | |
| P1433 | published in | Archives of Dermatology | Q15749524 |
| P1476 | title | Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management | |
| P478 | volume | 148 |
| Q36714398 | Analysis of dermatologic events in vemurafenib-treated patients with melanoma |
| Q38281838 | BRAF inhibitors: experience in thyroid cancer and general review of toxicity |
| Q40214785 | Case of vemurafenib-induced Sweet's syndrome |
| Q57035646 | Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology |
| Q38036715 | Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. |
| Q38139282 | Cutaneous adverse events to type I BRAF inhibitors: an analysis of effects associated with each inhibitor and therapeutic time interval to onset |
| Q38026916 | Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma |
| Q53063698 | Cutaneous side effects of anti-tumor therapy with BRAF and MEK inhibitors |
| Q38119710 | Cutaneous toxicities of BRAF inhibitors: Clinical and pathological challenges and call to action |
| Q38070436 | Cutaneous toxicities of RAF inhibitors. |
| Q60566835 | Cutaneous toxicities of new treatments for melanoma. |
| Q92464977 | Dermatologic conditions in women receiving systemic cancer therapy |
| Q38086762 | Dermatological adverse events from BRAF inhibitors: a growing problem. |
| Q38239381 | Dermatological toxicity associated with targeted therapies in cancer: optimal management |
| Q47256456 | Efficacy of Vemurafenib Treatment in 43 Metastatic Melanoma Patients with BRAF Mutation. Single-Institute Retrospective Analysis, Early Real-Life Survival Data. |
| Q38370667 | Erythema nodosum-like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature |
| Q48355954 | Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients |
| Q39111312 | IL-18 Regulates Melanoma VLA-4 Integrin Activation through a Hierarchized Sequence of Inflammatory Factors |
| Q35136819 | Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma |
| Q56893430 | Management of the cutaneous adverse effects of antimelanoma therapy |
| Q38215416 | Managing the skin toxicities from new melanoma drugs |
| Q40155438 | Melanoma patients under vemurafenib: prospective follow-up of melanocytic lesions by digital dermoscopy |
| Q38098593 | Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib |
| Q54372623 | Ponatinib-induced neutrophilic panniculitis |
| Q28488013 | RASopathic skin eruptions during vemurafenib therapy |
| Q40086569 | Recurrent Subcutaneous Sweet's Disease in a Myelofibrosis Patient Treated with Ruxolitinib before Allogeneic Stem Cell Transplantation |
| Q39321267 | Scurvy in a patient on vemurafenib |
| Q34582569 | Subcutaneous Sweet syndrome in the setting of myeloid disorders: A case series and review of the literature |
| Q37432850 | Systemic vasculitis associated with vemurafenib treatment: Case report and literature review |
| Q47549324 | The safety and efficacy of dabrafenib and trametinib for the treatment of melanoma |
| Q38203019 | The use of vemurafenib in Australian patients with unresectable or metastatic melanoma containing the V600 BRAF gene mutation |
| Q64987698 | Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. |
| Q55099672 | Unusual and Interesting Adverse Cutaneous Drug Reactions. |
| Q85468276 | Vasculitis and panniculitis associated with vemurafenib |
| Q35967342 | Vemurafenib and cutaneous adverse events--report of five cases |
| Q84612687 | Vemurafenib-induced neutrophilic panniculitis |
Search more.